An Experimental Ebola Vaccine

An Experimental Ebola Vaccine.
Early results suggest an conjectural Ebola vaccine triggers an inoculated response and is safe to use. However, larger clinical trials in West Africa are needed to settle if the immune response generated by the vaccine is large enough to protect against Ebola infection, said the researchers at Oxford University in the UK This vaccine insides against the Zaire character of Ebola currently circulating in West Africa. It doesn't contain catching Ebola virus material, so it cannot cause Ebola infection in people who receive it.

The vaccine is being developed by the US National Institutes of Health and GlaxoSmithKline. The fundamental doses of the vaccine for use in eminently clinical trials in West Africa have been delivered to Liberia. The Oxford University distress included 60 healthy volunteers who were monitored for 28 days after receiving three disparate doses of the vaccine. The volunteers will continue to be monitored for six months. "The vaccine was well tolerated.